Cetuximab (anti-EGFR)

製品コード：A2000         Batch: A200009

印刷

Cetuximab, a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation. MW : 145.781 KD.

製品説明

CAS No. 205923-56-4
Formulation 100 mM Pro-Ac, 20 mM Arg, pH5.0
Isotype Human IgG1
Source CHO cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping Shipped under low temperature conditions
Purity 99%
Protein concentration 7.55mg/ml
Endotoxin Level ＜1EU/mg

カスタマーフィードバック

Cetuximab-A200001X0120190320.gif

数据来源于[Data independently produced by , , J Thorac Oncol, 2018, 13(6):810-820]

Mice showed progression disease to first-line treatment were randomized 1:1 to the two arms of treatment and were treated until onset of progression disease or until the end-time of experiment in case of response (fixed to 52 weeks from the start of first-line therapy ), as indicated in in the Materials and Methods section. Growth curves of HCC827 xenografts treated in secondline with osimertinib plus selumetinib or cetuximab are represented as changes in the values of volumes as percentage compared to baseline tumor volume at the time of progression diasease to first-line (defined as 100%) for each case. Median tumor volume at PD2 was of 348 mm3.

Cetuximab-A200001Z0120180205.gif

数据来源于[Data independently produced by , , ]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

EV20-sss-vc/MMAF, an HER-3 targeting antibody-drug conjugate displays antitumor activity in liver cancer [ Oncology Reports, November 10, 2020, 776-785] PubMed: 33416143
Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model [ Molecular Cancer Therapeutics, November 01, 2023, 1319-1331]
The RASAL2 variant promotes aberrant RAS signaling and resistance to anti-EGFR therapy in colorectal cancer [ Scientific Reports, August 23, 2025, 31076] PubMed: 40849341
LPS-induced extracellular AREG triggers macrophage pyroptosis through the EGFR/TLR4 signaling pathway [ Frontiers in Immunology, April 11, 2025, 1549749] PubMed: 40292295
Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer [ Nat Commun, 2026, 17(1)3228] PubMed: 41986344
Overcoming adaptive resistance to KRASG12D blockade in pancreatic cancer through vertical pathway inhibition [ Clin Cancer Res, 2026, 32(11):2279-2292.] PubMed: 41801133
IL-1-mediated inflammation promotes metastatic dissemination and resistance to EGFR-targeted therapy [ NPJ Precis Oncol, 2026, 10(1):204.] PubMed: 41951719
Cetuximab co-treatment with KRAS G12C inhibitors fulzerasib and sotorasib in human KRAS G12C non-small cell lung cancer cells [ Cell Death Discov, 2026, 12(1)134] PubMed: 41786688
Artesunate Nanoplatform Targets the Serine-MAPK Axis in Cancer-Associated Fibroblasts to Reverse Photothermal Resistance in Triple-Negative Breast Cancer [ Adv Mater, 2025, e2502617] PubMed: 40528526
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells [ Nat Commun, 2025, 16(1):7853] PubMed: 40846697

人間や獣医の診断であるか治療的な使用のためにでない。